Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory
ALK tyrosine kinase inhibitor
Anaplastic lymphoma kinase
Brigatinib
Crizotinib
Non–small-cell lung cancer
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
19
07
2022
accepted:
19
07
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
7
9
2022
Statut:
epublish
Résumé
We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignancies. ALTA randomized patients with crizotinib-refractory In the phase 1/2 study, 79 of 137 brigatinib-treated patients had Brigatinib exhibited sustained long-term activity and PFS with manageable safety in patients with crizotinib-refractory
Identifiants
pubmed: 36065449
doi: 10.1016/j.jtocrr.2022.100385
pii: S2666-3643(22)00109-6
pmc: PMC9440305
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100385Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 The Authors.
Références
Drugs. 2021 Feb;81(2):267-275
pubmed: 33528789
Clin Cancer Res. 2016 Nov 15;22(22):5527-5538
pubmed: 27780853
J Clin Oncol. 2020 Nov 1;38(31):3592-3603
pubmed: 32780660
Future Oncol. 2021 May;17(14):1709-1719
pubmed: 33569983
J Thorac Oncol. 2017 Oct;12(10):1552-1560
pubmed: 28689043
J Clin Oncol. 2016 Mar 1;34(7):661-8
pubmed: 26598747
Clin Cancer Res. 2008 Jul 1;14(13):4275-83
pubmed: 18594010
J Clin Oncol. 2016 Aug 20;34(24):2866-73
pubmed: 27432917
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
J Clin Oncol. 2017 Aug 1;35(22):2490-2498
pubmed: 28475456
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
J Clin Oncol. 2011 May 20;29(15):e443-5
pubmed: 21422405
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
J Med Chem. 2016 May 26;59(10):4948-64
pubmed: 27144831
J Thorac Oncol. 2021 Dec;16(12):2091-2108
pubmed: 34537440
N Engl J Med. 2020 Nov 19;383(21):2018-2029
pubmed: 33207094
J Thorac Oncol. 2020 Mar;15(3):404-415
pubmed: 31756496
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lung Cancer. 2020 Jan;139:22-27
pubmed: 31706099
Lancet Oncol. 2016 Dec;17(12):1683-1696
pubmed: 27836716
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Eur J Cancer. 2017 Sep;82:27-33
pubmed: 28646771
Clin Cancer Res. 2013 Aug 1;19(15):4273-81
pubmed: 23729361
Lancet Oncol. 2015 Oct;16(13):e510-21
pubmed: 26433824
J Clin Oncol. 2016 Dec;34(34):4079-4085
pubmed: 27863201
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
J Thorac Oncol. 2021 Mar;16(3):452-463
pubmed: 33248320
J Clin Oncol. 2016 Aug 20;34(24):2858-65
pubmed: 27022118
Lancet Oncol. 2017 Jul;18(7):874-886
pubmed: 28602779